Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3714-3719

  Hope, William W ^a,b   Seibel, Nita L ^c   Schwartz, Cindy L ^d   Arrieta, Antonio ^e   Flynn, Patricia ^f   Shad, Aziza ^g   Albano, Edythe ^h   Keirns, James J ⁱ   Buell, Donald N ⁱ   Gumbo, Tawanda ^b   Drusano, George L ^b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

^e CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h CHILDREN S HOSPITAL   (United States)

ⁱ ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINOCANDIN; MICAFUNGIN;

AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BODY WEIGHT; CANDIDA; CANDIDIASIS; CHILD; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; HUMAN; IMMUNE DEFICIENCY; MONTE CARLO METHOD; PRIORITY JOURNAL; STATISTICAL MODEL;

ADOLESCENT; ALGORITHMS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; FEMALE; FORECASTING; HUMANS; LINEAR MODELS; LIPOPROTEINS; MALE; MODELS, STATISTICAL; MONTE CARLO METHOD; POPULATION;

EID: 34948887165     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00398-07     Document Type: Article

References (19)

1. Allegaert, K., B. J. Anderson, V. Cossey, and N. H. Holford. 2006. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br. J. Clin. Pharmacol. 61:39-48.
2. Almyroudis, N. G., S. M. Holland, and B. H. Segal. 2005. Invasive aspergillosis in primary immunodeficiencies. Med. Mycol. 43(Suppl. 1):S247-S259.
3. Anderson, B. J., A. D. McKee, and N. H. Holford. 1997. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. 33:313-327.
4. Benjamin, D. K., Jr., T. Driscoll, N. L. Seibel, C. E. Gonzalez, M. M. Roden, R. Kilaru, K. Clark, J. A. Dowell, J. Schranz, and T. J. Walsh. 2006. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50:632-638.
5. Benjamin, D. K., Jr., C. Poole, W. J. Steinbach, J. L. Rowen, and T. J. Walsh. 2003. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 112:634-640.
6. Bouwmeester, N. J., B. J. Anderson, D. Tibboel, and N. H. Holford. 2004. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth. 92:208-217.
7. Brown, J. H., G. B. West, and B. J. Enquist. 2000. Scaling in biology. Oxford University Press, Inc., New York, NY.
8. Castagnola, E., S. Cesaro, M. Giacchino, S. Livadiotti, F. Tucci, G. Zanazzo, D. Caselli, I. Caviglia, S. Parodi, R. Rondelli, P. E. Cornelli, R. Mura, N. Santoro, G. Russe, R. De Santis, S. Buffardi, C. Viscoli, R. Haupt, and M. R. Rossi. 2006. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr. Infect. Dis. J. 25:634-639.
9. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.esc.edu/.
10. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
11. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat. Rev. Microbiol. 2:289-300.
12. Dvorak, C. C., W. J. Steinbach, J. M. Brown, and R. Agarwal. 2005. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 36:621-629.
13. Heresi, G. P., D. R. Gerstmann, M. D. Reed, J. N. van den Anker, J. L. Blumer, L. Kovanda, J. J. Keirns, D. N. Buell, and G. L. Kearns. 2006. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr. Infect. Dis. J. 25:1110-1115.
14. Holford, N. H. 1996. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329-332.
15. Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. Proc. 14th IEEE Computer Soc, Bethesda, MD.
16. Seibel, N. L., C. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, J. Keirns, W. M. Lau, D. P. Facklam, D. N. Buell, and T. J. Walsh. 2005. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49:3317-3324.
17. Walsh, T. J., P. C. Adamson, N. L. Seibel, P. M. Flynn, M. N. Neely, C. Schwartz, A. Shad, S. L. Kaplan, M. M. Roden, J. A. Stone, A. Miller, S. K. Bradshaw, S. X. Li, C. A. Sable, and N. A. Kartsonis. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49:4536-4545.
18. Wurthwein, G., A. H. Groll, G. Hempel, F. C. Adler-Shohet, J. M. Lieberman, and T. J. Walsh. 2005. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob. Agents Chemother. 49:5092-5098.
19. Zaoutis, T. E., S. E. Coffin, J. H. Chu, K. Heydon, H. Zhao, H. M. Greves, and T. J. Walsh. 2005. Risk factors for mortality in children with candidemia. Pediatr. Infect. Dis. J. 24:736-739.